{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T22:28:52Z","timestamp":1792794532853,"version":"4.5.0"},"reference-count":23,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2021,1,18]],"date-time":"2021-01-18T00:00:00Z","timestamp":1610928000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Paratek Pharmaceuticals, Inc","id":[{"id":"https:\/\/ror.org\/019g7bh20","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Paratek Pharmaceuticals, Inc","id":[{"id":"https:\/\/ror.org\/019g7bh20","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,4,13]]},"abstract":"Abstract<\/jats:title>\n \n Objectives<\/jats:title>\n The objectives of this post-hoc analysis were to examine the safety and efficacy of omadacycline by BMI categories and diabetes history in adults with acute bacterial skin and skin structure infections (ABSSSI) from two pivotal Phase III studies.<\/jats:p>\n <\/jats:sec>\n \n Patients and methods<\/jats:title>\n OASIS-1 (ClinicalTrials.gov identifier NCT02378480): patients were randomized 1:1 to IV omadacycline or linezolid for 7\u201314\u2009days, with optional transition to oral medication. OASIS-2 (ClinicalTrials.gov identifier NCT02877927): patients received once-daily oral omadacycline or twice-daily oral linezolid for 7\u201314\u2009days. Early clinical response (ECR) was defined as \u226520% reduction in lesion size 48\u201372\u2009h after the first dose. Clinical success at post-treatment evaluation (PTE; 7\u201314\u2009days after the last dose) was defined as symptom resolution such that antibacterial therapy was unnecessary. Safety was assessed by treatment-emergent adverse events and laboratory measures. Between-treatment comparisons were made with regard to WHO BMI categories and diabetes history.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Patients were evenly distributed among healthy weight, overweight and obese groups. Clinical success for omadacycline-treated patients at ECR and PTE was similar across BMI categories. Outcomes by diabetes status were similar in omadacycline- and linezolid-treated patients: at ECR, clinical success rates were lower for those with diabetes; at PTE, clinical success was similar between treatment groups regardless of diabetes history. The safety of omadacycline and linezolid was largely similar across BMI groups and by diabetes history.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Omadacycline efficacy in patients with higher BMI and in patients with diabetes was consistent with results from two pivotal Phase III ABSSSI trials. Fixed-dose omadacycline is an appropriate treatment for ABSSSI in adults regardless of BMI.<\/jats:p>\n <\/jats:sec>","DOI":"10.1093\/jac\/dkaa558","type":"journal-article","created":{"date-parts":[[2020,12,21]],"date-time":"2020-12-21T15:20:38Z","timestamp":1608564038000},"page":"1315-1322","source":"Crossref","is-referenced-by-count":17,"title":["Safety and efficacy of omadacycline by BMI categories and diabetes history in two Phase III randomized studies of patients with acute bacterial skin and skin structure infections"],"prefix":"10.1093","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7119-5034","authenticated-orcid":false,"given":"Manjunath P","family":"Pai","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy, College of Pharmacy, University of Michigan, Ann Arbor, MI 48109, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark H","family":"Wilcox","sequence":"additional","affiliation":[{"name":"University of Leeds & Leeds Teaching Hospitals, Leeds LS2 9JT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Surya","family":"Chitra","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, PA 19406, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul C","family":"McGovern","sequence":"additional","affiliation":[{"name":"Paratek Pharmaceuticals, Inc., King of Prussia, PA 19406, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,17]]},"reference":[{"key":"2021041609051207600_dkaa558-B1","doi-asserted-by":"crossref","first-page":"S193","DOI":"10.1093\/cid\/ciz002","article-title":"Current epidemiology, etiology, and burden of acute skin infections in the United States","volume":"68 Suppl 3","author":"Kaye","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021041609051207600_dkaa558-B2","year":"2020"},{"key":"2021041609051207600_dkaa558-B3","volume-title":"Prevalence of Obesity Among Adults and Youth: United States, 2015\u20132016","author":"Hales","year":"2017"},{"key":"2021041609051207600_dkaa558-B4","first-page":"1783","article-title":"Obesity and risk of infections: results from men and women in the Swedish National March Cohort","volume":"48","author":"Ghilotti","year":"2019","journal-title":"Int J Epidemiol"},{"key":"2021041609051207600_dkaa558-B5","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s10654-020-00630-7","article-title":"Body mass index and risk of infections: a Mendelian randomization study of 101,447 individuals","volume":"35","author":"Winter-Jensen","year":"2020","journal-title":"Eur J Epidemiol"},{"key":"2021041609051207600_dkaa558-B6","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1056\/NEJMsa1909301","article-title":"Projected U.S. state-level prevalence of adult obesity and severe obesity","volume":"381","author":"Ward","year":"2019","journal-title":"N Engl J Med"},{"key":"2021041609051207600_dkaa558-B7","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/pds.3461","article-title":"The effect of obesity on antibiotic treatment failure: a historical cohort study","volume":"22","author":"Longo","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2021041609051207600_dkaa558-B8","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1592\/phco.27.8.1081","article-title":"Antimicrobial dosing considerations in obese adult patients: insights from the Society of Infectious Diseases Pharmacists","volume":"27","author":"Pai","year":"2007","journal-title":"Pharmacotherapy"},{"key":"2021041609051207600_dkaa558-B9","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1002\/phar.2023","article-title":"Comprehensive guidance for antibiotic dosing in obese adults","volume":"37","author":"Meng","year":"2017","journal-title":"Pharmacotherapy"},{"key":"2021041609051207600_dkaa558-B10","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1093\/clinids\/18.4.533","article-title":"Serum vancomycin concentrations: reappraisal of their clinical value","volume":"18","author":"Cant\u00fa","year":"1994","journal-title":"Clin Infect Dis"},{"key":"2021041609051207600_dkaa558-B11","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.addr.2014.05.016","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","journal-title":"Adv Drug Deliv Rev"},{"key":"2021041609051207600_dkaa558-B12","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1002\/jcph.505","article-title":"Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients","volume":"55","author":"Chung","year":"2015","journal-title":"J Clin Pharmacol"},{"key":"2021041609051207600_dkaa558-B13","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1002\/psp4.12146","article-title":"Fractal geometry-based decrease in trimethoprim-sulfamethoxazole concentrations in overweight and obese people","volume":"5","author":"Hall","year":"2016","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2021041609051207600_dkaa558-B14","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1056\/NEJMoa1800170","article-title":"Omadacycline for acute bacterial skin and skin-structure infections","volume":"380","author":"O\u2019Riordan","year":"2019","journal-title":"N Engl J Med"},{"key":"2021041609051207600_dkaa558-B15","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(19)30275-0","article-title":"Once-daily oral omadacycline versus twice-daily oral linezolid for acute bacterial skin and skin structure infections (OASIS-2): a phase 3, double-blind, multicentre, randomised, controlled, non-inferiority trial","volume":"19","author":"O\u2019Riordan","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"2021041609051207600_dkaa558-B16","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1093\/cid\/ciz396","article-title":"Omadacycline for acute bacterial skin and skin structure infections","volume":"69 Suppl 1","author":"Abrahamian","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021041609051207600_dkaa558-B17","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s12879-018-2975-2","article-title":"Diabetes and the occurrence of infection in primary care: a matched cohort study","volume":"18","author":"Abu-Ashour","year":"2018","journal-title":"BMC Infect Dis"},{"key":"2021041609051207600_dkaa558-B18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.2337\/dc17-2131","article-title":"Risk of infection in type 1 and type 2 diabetes compared with the general population: a matched cohort study","volume":"41","author":"Carey","year":"2018","journal-title":"Diabetes Care"},{"key":"2021041609051207600_dkaa558-B19","doi-asserted-by":"crossref","first-page":"S206","DOI":"10.1093\/cid\/ciz004","article-title":"Current treatment options for acute skin and skin-structure infections","volume":"68 Suppl 3","author":"Golan","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021041609051207600_dkaa558-B20","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/jac\/dky500","article-title":"Pharmacokinetic evaluation of linezolid administered intravenously in obese patients with pneumonia","volume":"74","author":"Xie","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"2021041609051207600_dkaa558-B21","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1093\/cid\/ciz398","article-title":"An integrated safety summary of omadacycline, a novel aminomethylcycline antibiotic","volume":"69 Suppl 1","author":"Opal","year":"2019","journal-title":"Clin Infect Dis"},{"key":"2021041609051207600_dkaa558-B22","author":"Lakota","year":"2018"},{"key":"2021041609051207600_dkaa558-B23","first-page":"P1943","author":"Lakota","year":"2019"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/5\/1315\/37042399\/dkaa558.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/76\/5\/1315\/37042399\/dkaa558.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,17]],"date-time":"2021-04-17T03:41:01Z","timestamp":1618630861000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/76\/5\/1315\/6103224"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,17]]},"references-count":23,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,1,17]]},"published-print":{"date-parts":[[2021,4,13]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaa558","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,5,1]]},"published":{"date-parts":[[2021,1,17]]}}}